ClusterOS Diagnostic Profile
Boston-Cambridge Life Sciences
Boston-Cambridge Life Sciences exhibits 5 observable stalls with Mediating instead of coupling and Re-proving instead of narrowing as primary behavioural patterns. 3 stabilisation stacks identified.
Re-proving (repeated accelerator program creation 2002-2017) co-occurs with Coordinating (repeated coordination entity creation 1985-2024). Each new program creates coordination demand; each coordination entity legitimates further program creation without requiring consolidation. Both operate across overlapping 15+ year windows.
Stabilising (continuity of Harvard hospitals, major pharma, established partnerships 2003-2024) co-occurs with Mediating (coordination entities, shared facilities, brokered partnerships). Incumbent stability creates demand for intermediation structures that reduce transaction costs; intermediation structures reduce pressure on incumbents to restructure or couple directly. Both operate across...
Coordinating (repeated coordination entity creation 1985-2024) co-occurs with Scaling activity (accelerator program expansion 2002-2017). Program activity expansion creates coordination demand; coordination entities enable program proliferation without requiring throughput accountability. Both operate across overlapping windows (2002-2024 intersection).
"If outcome data (venture formation, funding secured, survival rates) from university-operated programs were made comparable and visible across institutions, it might reduce the system's ability to absorb uncertainty about optimal venture support models without...
Leverage hypotheses are testable perturbations, not prescriptions. Where demand-side behaviour is weakly visible, the correct move is observation — improving visibility before attempting change.
A full ClusterOS diagnostic adds actor questionnaire data, working sessions, and anchor interviews — producing higher-confidence stall identification, board-ready stack analysis, and leverage hypotheses calibrated to your specific context.